The University of Debrecen, situated in Hungary's Debrecen city, is the country's oldest continuously functioning institution of higher education, dating back to 1538. The university offers an established English language program for international students, particularly in the field of medicine, which pioneered English education in 1986. Currently, nearly 5000 international students are enrolled at the university. The institution has a distinguished record, with five former students having won technical Academy Awards (Oscars) until 2014.

Tags

Neoplasms

Immune System Diseases

Skin and Musculoskeletal Diseases

Diagnostic radiopharmaceuticals

Radiolabeled antibody

Synthetic peptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Immune System Diseases	1

Top 5 Drug Type	Count

Radiolabeled antibody	2
Diagnostic radiopharmaceuticals	2
Synthetic peptide	1
Small molecule drug	1

Top 5 Target	Count

Kv1.3(Voltage-gated potassium channel subunit Kv1.3)	1
VEGF-A(Vascular endothelial growth factor A)	1
HVCN1(hydrogen voltage gated channel 1)	1
MUC1(Mucin-1)	1

Drugs associated with University of Debrecen

sVmKTx

Target

Kv1.3

Mechanism

Kv1.3 blockers

Active Org.

University of Debrecen

Originator Org.

University of Debrecen

Active Indication

Autoimmune Diseases

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

ClGBI

Target

HVCN1

Mechanism

HVCN1 blockers

Active Org.

University of Debrecen

Originator Org.

University of Debrecen

Active Indication-

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

52Mn-DOTAGA-Bevacizumab

Target

VEGF-A

Mechanism

VEGF-A modulators

Active Org.

University of Debrecen

Originator Org.

University of Debrecen

Active Indication

Uterine Cervical Cancer

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with University of Debrecen

CTIS2023-504745-31-00 / Not yet recruitingIIT

- AITT2023/3

Start Date12 Jun 2024

Sponsor / Collaborator

University of Debrecen

NCT06544980 / RecruitingNot ApplicableIIT

Measuring Upper Airway Cross Sectional Areas During Residual Neuromuscular Blockade and After Reserval

In our study, the investigators sought to answer the question of how the retroglossal pharyngeal areas measured after extubation of patients compare to baseline (before muscle relaxation) values. The investigators also investigated how these areas change as a function of TOF ratios measured at extubation, thus looking for a correlation between residual muscle relaxant effect and airway area.

Start Date02 Jan 2024

Sponsor / Collaborator

University of Debrecen

NCT05709184 / RecruitingNot ApplicableIIT

Lyophilized Fecal Microbiome Transfer for Primary Clostridioides Difficile Infection (DONATE Study): a Multicenter Randomized Controlled Trial

The goal of this clinical trial is to test whether lyophilized fecal microbime transfer - a dried extract of bacteria from the stool of healthy donors - is better than antibiotic therapy only for treating primary clostridioides difficile infection (CDI) in adult participants.
The main question it aims to answer is whether lyophilized fecal microbiome transfer lowers the number of episodes of CDI compared to antibiotic therapy.
Participants will be assigned to one of two groups:
In the intervention group participants will be given vancomycin by mouth for five days followed by 5 days of capsules of lyophilized fecal microbiome to swallow, up until day 10.
In the control group participants will be given vancomycin by mouth for ten days.
All participants will be asked to arrive for two follow-up visits and to fill out questionnaires. In addition, all participants will be asked to give stool samples before antibiotic therapy and on the two follow-up visits.
Researchers will compare the intervention group and the control group to see if there is a difference in symptoms degree after ten days and in recurrence of the infection after two months. They will also compare side effects, the total use of antibiotics and the change in the composition of bacteria in the stool, namely the presence of bacteria that are resistant to many drugs.

Start Date15 Nov 2023

Sponsor / Collaborator

Rambam Health Care Campus

[+6]

100 Clinical Results associated with University of Debrecen

0 Patents (Medical) associated with University of Debrecen

27,212

Literatures (Medical) associated with University of Debrecen

31 Dec 2024·Plant Signaling & Behavior

Vegetal memory through the lens of transcriptomic changes – recent progress and future practical prospects for exploiting plant transcriptional memory

Review

Author: Farkas, Dóra ; Dobránszki, Judit

Plant memory plays an important role in the efficient and rapid acclimation to a swiftly changing environment. In addition, since plant memory can be inherited, it is also of adaptive and evolutionary importance. The ability of a plant to store, retain, retrieve and delete information on acquired experience is based on cellular, biochemical and molecular networks in the plants. This review offers an up-to-date overview on the formation, types, checkpoints of plant memory based on our current knowledge and focusing on its transcriptional aspects, the transcriptional memory. Roles of long and small non-coding RNAs are summarized in the regulation, formation and the cooperation between the different layers of the plant memory, i.e. in the establishment of epigenetic changes associated with memory formation in plants. The RNA interference mechanisms at the RNA and DNA level and the interplays between them are also presented. Furthermore, this review gives an insight of how exploitation of plant transcriptional memory may provide new opportunities for elaborating promising cost-efficient, and effective strategies to cope with the ever-changing environmental perturbations, caused by climate change. The potentials of plant memory-based methods, such as crop priming, cross acclimatization, memory modification by miRNAs and associative use of plant memory, in the future's agriculture are also discussed.

31 Dec 2024·Plant Signaling & Behavior

Expression responses of XTH genes in tomato and potato to environmental mechanical forces: focus on behavior in response to rainfall, wind and touch

Article

Author: Dobranszki, Judit ; Gulyas, Andrea ; Toth, Bianka ; Hidvegi, Norbert

Rainfall, wind and touch, as mechanical forces, were mimicked on 6-week-old soil-grown tomato and potato under controlled conditions. Expression level changes of xyloglucan endotransglucosylase/hydrolase genes (XTHs) of tomato (Solanum lycopersicum L. cv. Micro Tom; SlXTHs) and potato (Solanum tuberosum L. cv. Desirée; StXTHs) were analyzed in response to these mechanical forces. Transcription intensity of every SlXTHs of tomato was altered in response to rainfall, while the expression intensity of 72% and 64% of SlXTHs was modified by wind and touch, respectively. Ninety-one percent of StXTHs (32 out of 35) in potato responded to the rainfall, while 49% and 66% of the StXTHs were responsive to the wind and touch treatments, respectively. As previously demonstrated, all StXTHs were responsive to ultrasound treatment, and all were sensitive to one or more of the environmental mechanical factors examined in the current study. To our best knowledge, this is the first study to demonstrate that these ubiquitous mechanical environmental cues, such as rainfall, wind and touch, influence the transcription of most XTHs examined in both species.

31 Dec 2024·Cogent Education

Influence of teachers’ emotional intelligence on students’ motivation for academic learning: an empirical study on university students of Bangladesh

Author: Rahman, Md. Hafizur ; Bin Amin, Mohammad ; Islam, Md. Aminul ; Yusof, Mohd Faizal ; Afrin, Sadia

News (Medical) associated with University of Debrecen

29 Sep 2022

·www.prnewswire.com

Lenire®, the treatment device shown to reduce tinnitus symptoms in 95% of patients, is now available in Hungary

More than 1 million Hungarians could experience tinnitus Tinnitus Klinika's 3 clinics will provide Lenire throughout Hungary Availability in Hungary follows publication of second large-scale clinical trial results, showing greater improvement in tinnitus symptoms BUDAPEST, Hungary, Sept. 29, 2022 /PRNewswire/ -- Irish medical device company, Neuromod Devices Ltd., which specialises in the treatment of tinnitus, has reached an agreement with Tinnitus Klinika kft, a provider of specialist tinnitus care, to make its Lenire device available in Hungary. Continue Reading Tamás Nagy, CEO & Owner of Tinnitus Klinika Tinnitus patient using Lenire Lenire is a bimodal neuromodulation device which has shown in analysis of real-world patients and multiple large-scale clinical trials to reduce the severity of tinnitus symptoms. Tinnitus, commonly known as "ringing in the ears", is a complex neurological condition resulting in the perception of sound without an external source. Landmark research into the prevalence of tinnitus in Europe was published in renowned scientific journal, The Lancet, in late 2021. It found that prevalence of any tinnitus was 14.7%i, which could mean that 1.4 million Hungarians experience the condition. Through this distribution agreement, Tinnitus Klinika's specialist team has exclusive licence from Neuromod to provide Lenire throughout Hungary to suitable patients for the treatment of their tinnitus. "I'm delighted to work with Tinnitus Klinika to make Lenire available to people living with tinnitus in Hungary. Tinnitus is globally recognised as a significant healthcare challenge and many people living with the condition have unmet clinical needs. Tinnitus specialists like Tinnitus Klinika deeply understand the needs of tinnitus patients and we're proud to be able to support them in improving therapeutic outcomes for their patients," explains Dr Ross O'Neill, Founder and CEO of Neuromod Devices. In the last 12 months Neuromod has expanded availability of Lenire in Europe, launching it in Denmark, Norway, Spain, Switzerland, and the UK. Earlier in 2022 the results of an independent real-world analysis were published in the peer-reviewed scientific journal, Brain Stimulation, demonstrating the safety and efficacy of the Lenire device for improving symptoms in tinnitus patients. The study found that 85% of tinnitus patients experienced a reduction in their tinnitus symptoms, as measured by THIii, following six to 12 weeks of treatment using Lenireiii. The device has also been used in large-scale clinical trials with over 500 patients. In June, the results of Lenire's second large-scale clinical trial were published in the highly regarded scientific journal, Nature – Scientific Reports. They showed a significant further breakthrough for improving tinnitus symptoms severity with Lenireiv. By changing the stimuli patients received halfway through their treatment plan, a clinically significant greater average improvement in tinnitus symptom severity was demonstratediv. 95% of treatment-compliant participants reported an improvement in their tinnitus symptoms, as measured by THIii,iv. 91% of treatment-compliant participants reported an improvement which sustained at least up to 12 months after treatment had endediv. Tinnitus Klinika's team have been providing specialist care for people living with tinnitus since it was founded in 2008 by Tamás Nagy, who holds a degree in Audiology from Oxford-Brookes University. The organisation operates 3 clinics in Hungary at Czeizel Institute in Budapest, Hallomás Center in Veszprém, and at Debrecen University in partnership with the University's Medical school. Tinnitus Klinika offers a suite of therapeutic interventions for people with tinnitus, which now includes Lenire, and has facilitated research of these interventions in their clinical practices under the guidance of the organisation's Advisory Board. "Tinnitus Klinika's partnership with Neuromod is a significant step forward for our tinnitus patients. I'm delighted to be able to provide an evidence-based treatment option that has seen encouraging patient outcomes in large-scale clinical trials and in the real world as part our suite of services for people living with the condition. I'm looking forward to working closely with Neuromod's team to achieve the best possible patient outcomes in our clinics ," explains Tamás Nagy, CEO at Tinnitus Klinika. Lenire is a bimodal neuromodulation device which combines mild electrical pulses to the tongue with sound stimulation to drive neuroplasticity in the brain which reduces the symptoms of tinnitus. It has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional and is currently available throughout Europe. The device consists of Bluetooth® headphones which play customised sounds to activate the auditory nerve, a proprietary intra-oral device which provides mild electrical stimulation to the surface of the tongue, known as a Tonguetip®, and a controller which controls the duration and intensity of treatment with the device. The device's sound and electrical stimuli can be calibrated to suit a patient's tinnitus after an initial assessment of their condition which includes an audiological exam. The supervising healthcare professional demonstrates how to use the device and provides the patient with instructions for use. Subsequently, patients use Lenire for 60 minutes per day typically for at least 10 weeks. Follow-up visits with the healthcare professional occur during treatment to monitor patients' progress. At the end of the prescribed treatment plan, the healthcare professional advises the patient about their continued use of Lenire. For more information please contact: Neil Doyle Global Director of Marketing, Neuromod Devices [email protected] About Neuromod Devices Ltd Founded in 2010, Neuromod Devices Ltd. is a medical technology company headquartered in Dublin, Ireland. Neuromod specialises in the design and development of neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic and debilitating conditions. The lead application of Neuromod's technology is in the field of tinnitus, where Neuromod has completed extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation platform in this common disorder. Neuromod's tinnitus treatment device, Lenire, is currently available throughout Europe. For more information visit . About Tinnitus Klinika kft Tinnitus Klinika kft, established in 2008, is a provider of specialist tinnitus care operating 3 clinics throughout Hungary at Czeizel Institute in Budapest, Hallomás Center in Veszprém, and at Debrecen University. Tinnitus Klinika provides a range of treatment interventions for people living with tinnitus. About Lenire Lenire is the first non-invasive bimodal neuromodulation tinnitus treatment device shown to soothe and relieve tinnitus in a large-scale clinical trial. Lenire has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe. Further details about Lenire including a list of providers can be found at . References (i) R. Biswas et al., Tinnitus prevalence in Europe: a multi-country cross-sectional population study, The Lancet Regional Health (2021), (ii) THI or Tinnitus Handicap Inventory is a clinical standard for measuring the impact of tinnitus on someone's day-to-day life. Measured on a scale of 100, the higher the score, the greater the impact of tinnitus. Reducing a person's THI score should correspond to improved quality of life by reducing how their tinnitus is affecting them. (iii) Buechner A, Lesinski-Schiedat A, Becker P, Lenarz T, Real-world clinical experience with bimodal neuromodulation for the treatment of tinnitus - A case series, Brain Stimulation (2022), doi: . (iv) Conlon et al., Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial, Sci Rep, (2022) Photo: Photo: SOURCE Neuromod Devices Ltd

Collaborate

100 Deals associated with University of Debrecen

100 Translational Medicine associated with University of Debrecen

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

sVmKTx ( Kv1.3 )	Autoimmune Diseases More	Preclinical
52Mn-DOTAGA-Bevacizumab ( VEGF-A )	Uterine Cervical Cancer More	Preclinical
ClGBI ( HVCN1 )	-	Preclinical
[111In]In-DOTA-PR81 ( MUC1 )	Breast Cancer More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis